4D Molecular Therapeutics Stock Forecast

Stock Price Forecast

According to 11 analysts polled by S&P Global, 4D Molecular Therapeutics stock has a consensus rating of "Buy" and an average price target of $28.22. The average 1-year stock price forecast is 219.59% higher than the current stock price, while the lowest is $17 (+92.53%) and the highest is $36 (+307.70%).

Price Target: $28.22 (+219.59%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$17	$28.22	$29	$36
Change	+92.53%	+219.59%	+228.43%	+307.70%

* Price targets were last updated on May 11, 2026.

Analyst Ratings

The average analyst rating for 4D Molecular Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Jan '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	7	7	7	7	7	7
Buy	2	2	2	2	2	2
Hold	2	2	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	11	11	11	11	11	11

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Matthew Caufield H.C. Wainwright	H.C. Wainwright	Buy Reiterates $36	Buy	Reiterates	$36	+307.70%	May 11, 2026
Geulah Livshits Chardan Capital	Chardan Capital	Buy Reiterates $26	Buy	Reiterates	$26	+194.45%	May 8, 2026
Lisa Walter RBC Capital	RBC Capital	Buy Maintains $35	Buy	Maintains	$35	+296.38%	May 8, 2026
Salveen Richter Goldman Sachs	Goldman Sachs	Buy Maintains $38 → $33	Buy	Maintains	$38 → $33	+273.73%	May 8, 2026
Daniel Giraldo Bank of America Securities	Bank of America Securities	Buy Reiterates $29	Buy	Reiterates	$29	+228.43%	May 8, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

11.60M

from 85.21M

-86.39%

from 85.21M

Revenue Next Year

17.51M

from 11.60M

50.93%

from 11.60M

EPS This Year

-3.92

from -2.42

EPS Next Year

-3.72

from -3.92

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	18.04M	3.13M	20.72M	37.00K	85.21M	11.60M
Revenue Growth	32.52%	-82.65%	562.29%	-99.82%	230,194.59%	-86.39%
Operating Income	-71.33M	-110.03M	-112.87M	-187.84M	-156.35M	-306.54M
Net Income	-71.32M	-107.49M	-100.84M	-160.87M	-140.11M	-275.67M
EPS	-	-	-	-	-2.42	-3.92
Free Cash Flow	-41.00M	-59.70M	-46.48M	-82.29M	-54.15M	-293.84M
No. Analysts	-	-	-	-	-	7

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	30.0M
Avg	11.6M
Low	3.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	-64.8%
Avg	-86.4%
Low	-96.5%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-3.92
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-